Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron in Pediatric Diffuse Pontine Gliomas
NCT00036569Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2002
- Primary completion
- Dec 2010
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2b in diffuse intrinsic pontine glioma (DIPG), sponsored by National Cancer Institute. Primary endpoints: 2-Year Survival Rate and Toxicities of PEG-Intron. Started May 2002; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT00036569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036569.